Physician profile
Daniel P Bouknight
NPI 1427057009
$9,779.42
in general payments reported to CMS, 2019-2025
46 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $1,088 · 2021: $1,734 · 2022: $1,306 · 2023: $904 · 2024: $1,300 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259 · Debt Forgiveness: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.42 |
| Debt Forgiveness | $972.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,353.47 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,078.40 | 2019-2024 | Xarelto |
| Amgen INC. | $1,057.99 | 2019-2025 | Repatha, Repatha |
| Lantheus Medical Imaging, INC. | $972.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $563.29 | 2020-2024 | Farxiga |
| Pfizer INC. | $433.52 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $418.20 | 2019-2023 | |
| Organogenesis INC. | $391.49 | 2021-2024 | Affinity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.17 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $303.50 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $282.62 | 2021-2025 | Verquvo |
| Astellas Pharma US INC | $264.96 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $251.57 | 2019-2024 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $246.03 | 2022-2025 | |
| Cvrx, INC. | $235.16 | 2024-2025 | Barostim Neo System |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $214.86 | 2019-2025 | |
| Esperion Therapeutics, INC. | $156.32 | 2020-2025 | Nexletol |
| Inari Medical, INC. | $133.72 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Atricure, INC. | $119.26 | 2025 | Synergy Ablation System |
| Convatec INC. | $114.34 | 2024 | |
| Alnylam Pharmaceuticals INC. | $100.45 | 2022-2025 | Onpattro |
| Boston Scientific Corporation | $66.62 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Stryker Corporation | $58.23 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abiomed | $57.97 | 2024 | Impella |
| Edwards Lifesciences Corporation | $53.29 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $48.64 | 2019-2024 | Praluent, Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $47.40 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $46.98 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $44.30 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $36.78 | 2022-2023 | Arcalyst |
| Abbott Laboratories | $31.75 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amarin Pharma, INC. | $27.12 | 2019-2021 | |
| Recor Medical INC | $24.89 | 2025 | Paradise Ultrasound Renal Denervation System |
| Biocompatibles, INC. | $24.24 | 2019 | |
| Beta Bionics, INC. | $23.73 | 2024 | Ilet Bionic Pancreas |
| Daiichi Sankyo INC. | $22.18 | 2022 | |
| Intra-Sana Laboratories | $20.94 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Infobionic, INC | $18.50 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.32 | 2023 | Quviviq |
| Genentech USA, INC. | $15.71 | 2021 | |
| Medtronic Vascular, INC. | $15.49 | 2019 | |
| Bard Peripheral Vascular, INC. | $14.73 | 2023 | Venclose Maven Catheter |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $14.44 | 2019 | |
| Medicomp INC | $14.38 | 2020 | |
| Lilly USA, LLC | $13.88 | 2023 | Mounjaro |
| Cashflow Solutions, LLC | $9.59 | 2024 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bouknight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.